Beta cells, which are critical for insulin production, are often destroyed or damaged in diabetes. Current treatments involve regular insulin injections, but the new approach aims to replace these cells. The therapy combines harmine, a naturally occurring molecule that inhibits the DYRK1A enzyme in beta cells, with a GLP1 receptor agonist, a class of diabetes drugs known to promote weight loss.
In the study, human beta cells were implanted into mouse models of type 1 and type 2 diabetes. Treatment with harmine and GLP1 receptor agonists resulted in a 700% increase in beta cells within three months and reversed the symptoms of diabetes.
News materials are not equivalent to a doctor’s prescription. Consult a specialist before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
